These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 11370054)
1. [Cancer incidence in the first-degree relatives of ovarian cancer patients]. Auranen A; Pukkala E; Mäkinen J; Sankila R; Grénman S; Salmi T Duodecim; 1997; 113(1):46-50. PubMed ID: 11370054 [No Abstract] [Full Text] [Related]
2. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991 [TBL] [Abstract][Full Text] [Related]
3. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. Olsen JH; Möller T; Anderson H; Langmark F; Sankila R; Tryggvadóttír L; Winther JF; Rechnitzer C; Jonmundsson G; Christensen J; Garwicz S J Natl Cancer Inst; 2009 Jun; 101(11):806-13. PubMed ID: 19470947 [TBL] [Abstract][Full Text] [Related]
4. Cancer incidence in first-degree relatives of a population-based set of cases of early-onset breast cancer. Rawal R; Bertelsen L; Olsen JH Eur J Cancer; 2006 Nov; 42(17):3034-40. PubMed ID: 16996259 [TBL] [Abstract][Full Text] [Related]
5. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860 [TBL] [Abstract][Full Text] [Related]
6. Cancer. A risky business--assessing breast cancer risk. Levy-Lahad E; Plon SE Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407 [No Abstract] [Full Text] [Related]
7. Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian cancer. van Asperen CJ; Jacobi CE; de Bock GH Br J Cancer; 2005 Apr; 92(7):1336-7; author reply 1337-8. PubMed ID: 15785743 [No Abstract] [Full Text] [Related]
8. Timing of familial breast cancer in sisters. Rebora P; Czene K; Reilly M J Natl Cancer Inst; 2008 May; 100(10):721-7. PubMed ID: 18477799 [TBL] [Abstract][Full Text] [Related]
9. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400 [TBL] [Abstract][Full Text] [Related]
10. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514 [TBL] [Abstract][Full Text] [Related]
11. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447 [TBL] [Abstract][Full Text] [Related]
12. Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives. Bertelsen L; Mellemkjaer L; Christensen J; Rawal R; Olsen JH Epidemiology; 2009 Mar; 20(2):175-80. PubMed ID: 19057388 [TBL] [Abstract][Full Text] [Related]
13. Cervical, endometrial and ovarian cancers among immigrants in Sweden: importance of age at migration and duration of residence. Beiki O; Allebeck P; Nordqvist T; Moradi T Eur J Cancer; 2009 Jan; 45(1):107-18. PubMed ID: 18829301 [TBL] [Abstract][Full Text] [Related]
14. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259 [TBL] [Abstract][Full Text] [Related]
15. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses. Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156 [TBL] [Abstract][Full Text] [Related]
16. [Genetic epidemiology study of ovarian cancer. I. A comparison of familial and population frequencies]. Chudina AP; Akulenko LV Genetika; 1984 May; 20(5):849-56. PubMed ID: 6539727 [TBL] [Abstract][Full Text] [Related]
18. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. King MC; Marks JH; Mandell JB; Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434 [TBL] [Abstract][Full Text] [Related]
19. [Ovarian cancer and borderline tumors]. Bjørge T; Engeland A; Hansen S; Tropé CG Tidsskr Nor Laegeforen; 1998 Jun; 118(16):2471-5. PubMed ID: 9667122 [TBL] [Abstract][Full Text] [Related]
20. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation. Suthers GK ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]